Covax to purchase 40M doses of Pfizer, BioNTech COVID-19 vaccine

By The Science Advisory Board staff writers

January 25, 2021 -- The Covax global vaccine initiative has reached a deal with Pfizer and BioNTech for 40 million doses of the Pfizer-BioNTech COVID-19 vaccine.

The Covax initiative was established by leading public health agencies, including the World Health Organization, to provide governments with early access to a large portfolio of COVID-19 vaccines. The new advance purchase agreement secures 40 million doses to be delivered throughout 2021.

The first doses are expected to be delivered in the first quarter of the year, and Pfizer and BioNTech will provide the vaccine to 92 low- and middle-income countries for not-for-profit pricing.

Terms of the agreement were not disclosed. The delivery is subject to supply agreements under the Covax Facility structure.

Pfizer invests $120M in biotech innovation
Pfizer has invested $120 million in four clinical-stage biotech companies as part of its Pfizer Breakthrough Growth Initiative.
EC authorizes Pfizer, BioNTech COVID-19 vaccine
The European Commission (EC) has granted a conditional marketing authorization to Pfizer and BioNTech for their COVID-19 vaccine.
Pfizer, BioNTech get positive CHMP recommendation for COVID-19 vaccine
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion to recommend the conditional...
Pfizer, BioNTech finalize supply deal with EU for COVID-19 vaccine
Pfizer and BioNTech, developers of BNT162b2, a messenger RNA-based SARS-CoV-2 vaccine candidate, have reached an agreement with the European Commission...
Pfizer, BioNTech get $1.95B for SARS-CoV-2 vaccine
Pfizer and BioNtech have inked an agreement with the U.S. Department of Health and Human Services and the Department of Defense, as part of the federal...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter